Company profile

Shenyang Sunshine Pharmaceutical

Privately held: no public share price

Assets

(4 total)
4Total Assets
0Approved
2Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
PF-08634404
Phase 3
PD-1 + VEGFMultispecific antibody
Non-Small Cell Lung Cancer
rESP
Phase 3
Erythropoietin receptor (EPO-R)Biologic — subtype unspecified
Chronic Kidney Disease
SSGJ-706
Phase 2
PD-1 and PD-L1Multispecific antibody
Non-Small Cell Lung Cancer
SSS17
Phase 2
HIF prolyl hydroxylase (HIF-PH1/2/3)Small molecule
Chronic Kidney Disease

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.